Authors: Wang L et al.
Anesthesia & Analgesia, 2026.
Interpreting Length-of-Stay Benefits of Intrathecal Morphine in Modern Enhanced Recovery After Surgery Pathways.
This letter to the editor discusses the interpretation of a randomized controlled trial evaluating the effect of intrathecal morphine (ITM) on hospital length of stay after joint arthroplasty within enhanced recovery after surgery (ERAS) protocols. The authors commend the original investigators for conducting a rigorous double-blinded randomized study but highlight several considerations that may influence how the findings should be interpreted in modern perioperative practice.
The trial reported that intrathecal morphine reduced hospital length of stay from approximately 44.2 hours to 30.0 hours after arthroplasty. While this difference reached statistical significance, the letter argues that the mechanism underlying the reduced length of stay remains uncertain.
One explanation proposed by the original authors was that improved analgesia facilitated earlier discharge. However, the letter points out that discharge readiness in ERAS pathways depends on multiple factors beyond pain control, including mobility, ambulation distance, standardized pain thresholds, and validated independence scores. Variability in discharge criteria across institutions could influence observed differences in length of stay.
The authors note that the interquartile ranges for hospital stay overlapped substantially between the intrathecal morphine and control groups. This suggests that differences in discharge practices or institutional protocols could partially account for the observed results. They suggest that future studies should include standardized functional recovery metrics to determine whether intrathecal morphine truly accelerates physiologic recovery or simply coincides with earlier discharge decisions.
The letter also acknowledges challenges related to the study’s recruitment period, which spanned 2019 to 2023 and overlapped with the COVID-19 pandemic. Pandemic-related changes in hospital policies, staffing, and discharge processes may have influenced enrollment patterns and clinical decision-making. Additional information about enrollment distribution across time periods could clarify whether these external factors affected results.
Another point raised concerns pain assessment timing. Pain scores reported in the original trial were measured before 24 hours after surgery. Because intrathecal morphine typically provides peak analgesic effects during the first 12 to 18 hours, the absence of later pain measurements may limit interpretation of how long the analgesic benefits persist and whether they meaningfully influence recovery milestones.
The authors also note that the study excluded patients undergoing urinary procedures, which may limit generalizability. Many arthroplasty patients have comorbid conditions such as benign prostatic hyperplasia that could affect postoperative recovery.
Despite these considerations, the letter recognizes that the findings remain clinically meaningful. Current PROSPECT guidelines recommend intrathecal morphine as part of regional anesthesia strategies for lower limb arthroplasty analgesia. The reported reduction in length of stay—from 39% to 32% in the risk balance analysis—may still represent a relevant improvement within ERAS pathways.
The authors conclude that the study provides important evidence supporting the use of intrathecal morphine but emphasize the need for future research using standardized ERAS metrics, broader patient populations, and more detailed functional recovery measurements to determine whether length-of-stay reductions truly reflect improved recovery.
Key Points
• A randomized trial reported reduced hospital length of stay with intrathecal morphine after arthroplasty within ERAS pathways.
• The mechanism for the reduced length of stay remains uncertain and may not be solely related to analgesia.
• Discharge readiness depends on multiple ERAS milestones including mobility and functional independence.
• Overlapping length-of-stay distributions suggest discharge practices may influence results.
• Pandemic-era recruitment may have affected enrollment and discharge policies.
• Intrathecal morphine remains recommended in PROSPECT guidelines for arthroplasty analgesia.
Thank you to Anesthesia & Analgesia for allowing us to summarize and share this article.